Jupiter, FL – [September 12th, 2024] – Myosin Therapeutics is pleased to announce the expansion and strengthening of its patent portfolio for its lead compounds MT-110 and MT-125, with newly granted and issued status in the key jurisdictions of Australia, Japan, Canada, and Korea. These recent grants build upon the company’s exclusively licensed patent family, originally developed at Scripps Florida (now Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology), solidifying Myosin’s global intellectual property position.
The seminal discoveries that led to the development of MT-110 and MT-125 were made by the founders of Myosin Therapeutics while at Scripps Florida.
These new patent grants in Australia, Japan, Canada, and Korea further reinforce Myosin’s ability to actively pursue partnerships, funding, and collaborations in key markets. The expanded patent protection not only covers the composition and use of MT-110 and MT-125, but also supports the company’s ongoing efforts to advance these novel therapeutic compounds through clinical development for the treatment of cancer and substance use disorder.
Myosin Therapeutics continues to expand its intellectual property. “Our recently granted patents in Australia, Japan, Canada, and Korea significantly bolster our global IP position and support the clinical advancement of MT-110 and MT-125,” said Dr. Courtney Miller, Chief Executive Officer of Myosin Therapeutics. “This expanded protection is a key milestone in our strategy to bring novel therapeutics to market and engage with strategic partners worldwide.”
About Myosin Therapeutics
Myosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of the Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for oncology and central nervous system indications with a platform for targeting molecular nanomotor proteins. Myosin’s lead programs for glioblastoma and stimulant use disorder target non-muscle myosin II motor proteins.
For more information, email contact@myosintherapeutics.com
